The allotment for the Rubicon Research IPO is anticipated to be finalized on Tuesday, October 14, 2025. Investors can verify the final allotment on the NSE, BSE, and MUFG Intime India websites. The IPO received a robust response, with a share price ranging from ₹461 to ₹485. The total subscription reached 103.90 times, with a total of 1,70,96,80,620 shares bid for against 1,64,55,670 shares available. Subscription rates by category include Qualified Institutional Buyers at 130.26 times, Non-Institutional Investors at 97.61 times, and Retail Investors at 35.47 times. The IPO aims to raise ₹1,377.50 crore, comprising ₹500 crore from new shares and ₹877.50 crore from a promoter sale. Proceeds will be allocated for loan repayments, acquisitions, and general business needs.
Rubicon Research specializes in pharmaceutical R&D, producing specialty products and drug-device combinations for regulated markets.